Abstract: A method and apparatus for hydrocracking mineralized refuse pyrolysis oil. The method may use the following steps: (a) crushing and pyrolyzing mineralized refuse to obtain arene and alkane precursor biomass oil; (b) hydrogenating the arene and alkane precursor biomass oil obtained in step (a), and separating the obtained hydrocrackate to obtain arene and alkane; and (c) purifying, recovering and optimizing the arene and alkane obtained in step (b), and performing deep processing to produce naphtha, jet fuel, light diesel oil, and heavy diesel oil.

Abstract: A network topology determining apparatus includes: an obtaining module, configured to obtain a connection relationship between a plurality of network elements in a network and a network grade of each network element, where the network grade is used to indicate an importance degree of the network element in the network; a first determining module, configured to determine a plurality of subnets based on the connection relationship between the plurality of network elements and the network grade of each network element; a second determining module, configured to determine location information of each network element in a descending order of the network grades of the network elements in the network based on a connection relationship between network elements in each subnet; and an establishment module, configured to establish a network topology based on the connection relationship between the plurality of network elements and the location information of each network element.

Abstract: There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.

Abstract: There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids.